ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017
Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Age-specific differences in tumour characteristics between screen-detected and non-screen-detected breast cancers in women aged 40-74 at diagnosis in Sweden from 2008 to 2017.Journal of medical screening · 2024Article
- Age-specific differences in breast cancer treatment between screen-detected and non-screen-detected breast cancers in women aged 40-74 years at diagnosis in Sweden 2008-2017.Acta oncologica (Stockholm, Sweden) · 2024Article
- Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan.Breast cancer (Tokyo, Japan) · 2024Observational
- Impact of the COVID-19 pandemic on breast cancer pathological stage at diagnosis in Tunisian patients.Breast disease · 2024Article
- Evaluation of a population-based breast cancer screening in North China.Journal of cancer research and clinical oncology · 2023Article
- A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer.Science China. Life sciences · 2022Article
- Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes.Cancers · 2022Article
- Article
- Screen-detected breast cancer is associated with better prognosis and survival compared to self-detected/symptomatic cases in a Chilean cohort of female patients.Breast cancer research and treatment · 2021Article
- Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis.Breast cancer research and treatment · 2021Article
- Which type of cancer is detected in breast screening programs? Review of the literature with focus on the most frequent histological features.Pathologica · 2021Review
- Differences in clinicopathologic features and subtype distribution of invasive breast cancer between elderly and non-elderly women.Fujita medical journal · 2021Article
- Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes.Fujita medical journal · 2021Article
- Breast cancer screening of mutation carriers in the era of COVID-19 pandemic.International journal of cancer · 2020Article
- Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers.Cancers · 2020Article
- Impact of adjuvant chemotherapy on the survival of patients with breast cancer diagnosed by screening.Cancer medicine · 2019Article
- Differences in clinicopathologic features and subtype distribution of invasive breast cancer between women older and younger than 40 years.Fujita medical journal · 2019Article
- Inverse correlation between Ki67 expression as a continuous variable and outcomes in luminal HER2-negative breast cancer.Fujita medical journal · 2019Article
- Prognostic values of distinct CBX family members in breast cancer.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStage shift is considered a major reason for more favorable outcomes in patients with screen-detected breast cancer. However, even after adjusting for clinical stage, unresolved issues concerning the reasons for a survival benefit associated with screening programs remain. This study aims to evaluate differences in subtype distribution and outcomes among patients with screen-detected and symptomatic invasive breast cancer and assess whether variations in subtype distribution could explain differences in prognosis.
methodsSurvival analysis was performed to estimate the likelihood of distant recurrence and death in 1132 patients. Subtypes were defined as luminal A [estrogen receptor (ER)+ and/or progesterone receptor (PR)+, human epidermal growth factor receptor 2 (HER2)-, and Ki67 low], luminal B (HER2-) (ER+ and/or PR+, HER2-, and Ki67 high), luminal B (HER2+) (ER+ and/or PR+ and HER2+), HER2 overexpressing (ER-, PR-, and HER2+), and triple negative (ER-, PR-, and HER2-).
resultsScreen-detected cancers had favorable clinicopathological characteristics, such as smaller tumor size and a lower frequency of lymph node involvement. Women with screen-detected cancers had a survival advantage. Subtype distribution differed significantly among women with screen-detected and symptomatic cancer. Screen-detected cancers were more likely to be luminal A and less likely to be HER2 overexpressing or triple negative cancer compared with symptomatic cancers (luminal A 61.3 vs. 44.2%, HER2 overexpressing 4.0 vs. 8.0%, triple negative 8.0 vs. 15.9%). Node status, mode of detection, and subtype were independent prognostic factors in the multivariate analysis.
conclusionsDifferences in subtype distribution between screen-detected and symptomatic cancer could partially explain differences in outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.